Jul 18, 2023
CHARLOTTESVILLE, Va. and CARMEL, Ind., July 18, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen”) (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease
Jul 16, 2023
Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody Rapid, dose-related, statistically significant (p=0.01) amyloid plaque reduction observed within higher
Jun 13, 2023
Topline results for ACU193, the first clinical stage amyloid beta oligomer (A βO)-directed antibody, to provide deeper insight into candidate’s therapeutic potential for the treatment of early Alzheimer’s disease Phase 1 INTERCEPT-AD data investigating safety, pharmacokinetics and target engagement
Displaying 1 - 10 of 19